Jefferies Boosts Olema Oncology Price Target on Strong SERD Momentum
Jefferies raises Olema Oncology’s price target to $43 as new Roche giredestrant data strengthens confidence in next-generation SERDs and multibillion-dollar market potential.
/ 907 items
#Healthcare↓
Hims Stock Dips as New SAFE Drugs Act Targets Compounded Weight-Loss Medications
Hims shares fell after lawmakers proposed the SAFE Drugs Act, a bill that would restrict compounded versions of popular GLP-1 weight-loss drugs. Analysts say the bill could significantly impact Hims’ fastest-growing product category.
Republicans Consider Medicare Hospital Pay Cuts to Counter Obamacare Subsidy Demands
GOP lawmakers explore site-neutral Medicare payments for hospitals as they search for alternatives to extending expiring Affordable Care Act subsidies affecting 20+ million Americans.
HeartBeam Gets FDA Green Light for Home Heart Monitoring Device
HeartBeam receives FDA clearance for credit-card sized device that delivers 12-lead ECG heart readings at home for arrhythmia detection without cables or wires.
Oppenheimer Upgrades Compass Pathways on Growing Confidence in COMP360
Oppenheimer upgrades Compass Pathways to Outperform with a $15 target, citing rising conviction that COMP360 psilocybin therapy could become the first FDA-approved psychedelic treatment for depression.
HSBC Cuts Biogen Rating as MS Business Weakens
HSBC downgraded Biogen to Reduce, citing weakness in its multiple sclerosis business, margin pressure, and limited near-term earnings growth.